NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company specializing in minimally invasive solutions for neurological disorders, announced it will release its fiscal third quarter 2026 financial results before market open on Thursday, August 13, 2026. The announcement was made via a press release on August 3, 2026.
The company will host an investor conference call and webcast at 8:30 a.m. Eastern time on the same day to discuss the financial results, provide a corporate update, and answer questions from telephone participants. Interested parties can join the call by dialing 888-506-0062 (toll-free) for U.S. callers or 973-528-0011 for international callers, using participant access code 549778. A live webcast will also be available at NMTC FY Q3 2026 Earnings Call Webcast. Participants are advised to dial in at least five minutes before the start of the call to ensure timely participation.
A replay of the call will be available through August 27, 2026, by calling 877-481-4010 (U.S.) or 919-882-2331 (international) with replay passcode 54304. The webcast replay will be accessible via the same link until August 13, 2027.
NeuroOne focuses on improving surgical care for patients with neurological disorders through its high-definition, high-precision electrode technology platform. The company markets four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These products are designed to potentially reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions.
The upcoming financial results will provide insights into the company's performance for the quarter ended June 30, 2026, and its progress in advancing its product pipeline, which includes drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. Investors and industry observers will be keen to see how NeuroOne is capitalizing on its FDA-cleared products and whether its research and development efforts are translating into growth opportunities.
The announcement comes at a time when the medical technology sector is seeing increased demand for minimally invasive solutions that can reduce healthcare costs and improve patient recovery times. NeuroOne's focus on both diagnostic and therapeutic applications positions it well to address these market needs.
For more information about NeuroOne and its products, visit the company's website at nmtc1.com.
